post_grad
Contact the Center

Administrative Contact:
Barbara Dearry
919-843-0766
dearry@email.unc.edu

Join Us

Interested in working at the Center? Check out our job opportunities page.

 
You are here: Home / Research / Centers / Center for Integrative Chemical Biology and Drug Discovery

Center for Integrative Chemical Biology and Drug Discovery

The Center for Integrative Chemical Biology and Drug Discovery was created with the mission of bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. Synthetic chemists, assay development and compound profiling scientists will work in the Center and create dedicated, multidisciplinary project teams with other groups on campus in order to progress targets through the drug discovery and development process.  The Center provides leadership of the North Carolina Comprehensive Chemical Biology Center, a member of NCI's Chemical Biology Consortium.
 

Research & Funding News

 

The Melanoma Research Alliance and the Saban Family Foundation announce Team Science Award to conduct study: "TAMs in melanoma: Mechanisms and therapeutic efficacy of novel inhibitors.”  Award funds collaboration with Hebrew University, University of Colorado Anschutz Medical Campus, and UNC researchers in the CICBDD and Lineberger Comprehensive Cancer Center.  More

A Chemical Tool for in vitro and in vivo Precipitation of the Lysine Methyltransferase G9a published by Jin group and collaborators in ChemMedChem, 2014, DOI: 10.1002/cmdc.201300450.  View inside cover image by Kyle Konze and Samantha Pattenden.

Bill Janzen and collaborator Cyrus Vaziri (lead PI) receive NIH grant targeting the TLS DNA Damage Tolerance Pathway for Cancer Therapy.   Read More

Erythropoietin Promotes Breast Tumorigenesis Through Tumor Initiating Cell Self-renewal published by Jian Jin and collaborators in J. Clin. Investig. 2014, DOI: 10.1172/JCI69804. 

Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors  published by Weihe Zhang et al., in J. Med. Chem. 2013, 56, 9683-9692.

Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis published by Weihe Zhang et al.  in J. Med. Chem.  2013, 56, 9693-9700.

Small-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3 published by Lindsey James et al. in J. Med. Chem., Article ASAP,  DOI: 10.1021/jm400919p,  online Sept. 16, 2013.

The structure-activity relationships of L3MBTL3 inhibitors: A second series of potent compounds which bind the L3MBTL3 dimer, manuscript by Camerino et al. accepted by Med. Chem. Commun.,  DOI: 10.1039/C3MD00197K,  published online 17 Sep 2013.

Jian Jin receives a three-year $950,000 grant will support efforts to create in vivo chemical probes for studying the proteins G9a and GLP, which are relatively new potential drug targets. See also ESOP feature.

Chemical probe for the L3MBTL3 methyllysine reader domain featured on cover of Nature Chemical Biology, January 2013. See paper by Lindsey James et al. in collaboration with the Structural Genomics Consortium and U. Toronto.    Article Cover See also ESOP feature.

Efficient Solution-Phase Synthesis of 4,5,7-Trisubstituted Pyrrolo[3,2-d]pyrimidines published by Weihe Zhang et al. in ACS Combinatorial Science, 2013, 15 (1), pp 10–19.

Document Actions